Al m\u00f3n hi ha 500 milions de persones que pateixen diabetis. Aquesta malaltia representa un factor de risc cardiovascular rellevant, ja que fa que la glucosa s\u2019acumuli a la sang i danyi progressivament els vasos sanguinis, accelerant l\u2019arterioesclerosi. Quan cal tractar les persones amb diabetis d\u2019un problema coronari amb cateterisme i col\u00b7locaci\u00f3 de stent, els resultats s\u00f3n clarament pitjors que els que s\u2019obtenen en poblaci\u00f3 no diab\u00e8tica.<\/p>\n
Segons explica el Dr. Romaguera, \u201cels resultats dels stents farmacoactius que s\u2019havien desenvolupat fins ara eren molt bons en pacients no diab\u00e8tics per\u00f2 clarament millorables en pacients diab\u00e8tics; per aquest motiu, era important provar nous dispositius i estrat\u00e8gies en aquest grup de pacients d\u2019alt risc\u201d.<\/p><\/blockquote>\n
<\/p>\n
L\u2019any 2017, un primer estudi d\u2019investigadors de Bellvitge basat en el control angiogr\u00e0fic (estudi RESERVOIR), ja va posar en relleu l\u2019efic\u00e0cia d\u2019un nou stent que allibera una combinaci\u00f3 de f\u00e0rmacs anomenada amphilimus, <\/em>i, a difer\u00e8ncia d\u2019altres, ho fa sense acompanyar-lo d\u2019un pol\u00edmer (element que ajuda a dosificar el f\u00e0rmac per\u00f2 que, alhora, podria causar reaccions inflamat\u00f2ries). Per confirmar aquests resultats prometedors, es va dissenyar l\u2019actual investigaci\u00f3 (estudi SUGAR) de seguiment dels resultats cl\u00ednics a llarg termini del nou dispositiu.<\/p>\n <\/p>\n
Realitzat amb el suport de la Societat Espanyola de Cardiologia, l\u2019estudi SUGAR va randomitzar un total de 1.175 pacients de 23 hospitals espanyols. A un grup de pacients se\u2019ls va implantar el nou stent alliberador d\u2019amphilimus, i, a la resta, un stent farmacoactiu d\u2019\u00fas habitual que allibera el f\u00e0rmac zotarolimus i un pol\u00edmer.<\/p>\n
<\/p>\n
Al cap d\u2019un any de seguiment, s\u2019ha comprovat que els pacients que han estat tractats amb el nou stent han tingut un 35% menys de problemes greus (mortalitat, nou infart, o nou episodi d\u2019estrenyiment arterial a la zona tractada amb l\u2019stent).<\/p>\n
<\/p>\n
Romaguera destaca que aquests resultats representen \u201cla primera millora que apareix en m\u00e9s de deu anys en el tractament amb cateterisme coronari dels pacients diab\u00e8tics\u201d. Aix\u00ed mateix, considera que s\u00f3n resultats prou consistents com per implicar efectes immediats en la pr\u00e0ctica cl\u00ednica, de manera que aquest nou dispositiu hauria de passar a ser considerat com l\u2019stent de refer\u00e8ncia per al tractament dels pacients diab\u00e8tics.<\/p>\n","protected":false},"excerpt":{"rendered":"
La seva major efectivitat s\u2019ha constatat en un estudi coordinat des de l\u2019Hospital de Bellvitge i IDIBELL. El nou dispositiu redueix un 35% el nombre de complicacions greus al cap d\u2019un any de la intervenci\u00f3. L\u2019estudi s\u2019ha publicat a la revista cardiovascular m\u00e9s important del m\u00f3n.<\/p>\n","protected":false},"author":8,"featured_media":19438,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[359,334,466],"tags":[],"class_list":["post-19437","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-malalties-cardiovasculars","category-medicina-translacional","category-p-de-malalties-cardiovasculars-respiratories-sistemiques-i-denvelliment-cellular"],"publishpress_future_action":{"enabled":false,"date":"2025-01-19 01:31:30","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/19437","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=19437"}],"version-history":[{"count":3,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/19437\/revisions"}],"predecessor-version":[{"id":19441,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/19437\/revisions\/19441"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/19438"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=19437"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=19437"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=19437"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}